Finanzen von Sunshine Biopharma Inc (SBFM)SBFMSunshine Biopharma Inc

Evaluating the bottom line, Sunshine Biopharma Inc maintains a gross margin of 25.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.41%, while the net margin is -16.88%. These profitability ratios, combined with a Return on Equity (ROE) of -21.93%, provide a clear picture of how effectively SBFM converts its operational activities into shareholder value.

In the context of the broader market, SBFM competes directly with industry leaders such as SILO and SXTC. With a market capitalization of $2.06M, it holds a significant position in the sector. When comparing efficiency, SBFM's gross margin of 25.35% stands against SILO's -14.77% and SXTC's 28.74%. Such benchmarking helps identify whether Sunshine Biopharma Inc is trading at a premium or discount relative to its financial performance.

The company has consistently reported negative net income, with losses reaching -2,143,927 USD in Q4 2025 and -1,564,048 USD in Q2 2026. The gross margin is also declining, currently at 25.35% for Q2 2026, down from 35.60% in Q2 2025.